Nestlé (NSRGY) and Aimmune Therapeutics (AIMT) $2.6bn acquisition information including expected completion date, offer price and contact details are displayed in the acquisition details table below. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
This deal was successfully consummated on October 12, 2020
Aimmune Therapeutics (AIMT) Acquisition
Receive FREE instant access to constantly updated AIMT news related to the current acquisition. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click Aimmune Therapeutics (AIMT). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box such as “AIMT“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders and shareholders can review similar acquisition details on current takeover stocks by first selecting “DEALS” from the main menu above, then “Current Cash Deals” or “Current Stock Deals“. For previous acquisitions, select either “Closed Deals” or “Failed Deals“. See our Spread Tracker News for mergers and acquisitions updates on the existing T20 Index portfolio constituents. Additionally, check out our customized M&A PR Newswire or Business Wire press release news feeds exclusively for Merger Arbitrage Limited.
Aimmune Therapeutics (NASDAQ: AIMT) Acquisition - Merger News and Events
The major acquisition news updates & events of Aimmune Therapeutics (AIMT) by Nestlé (NSRGY) are listed below. A comprehensive data source for
- Traders looking to familiarize themselves with the Nestlé (NSRGY) buyout of Aimmune Therapeutics (AIMT) and trade the merger arbitrage spread
- Existing shareholders and investors wishing to stay abreast of the latest deal developments.
Following the acquisition news section, there is an in-depth company profile.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow’s milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial.
The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
